STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .
ElBordiny, M., Ghandor, A., Atteya, A., Abo Elwafa, R., ElSokaily, A. (2022). STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .. EKB Journal Management System, 4(4), 33-34. doi: 10.21608/alexpo.2022.174858.1510
Magdy Mamdouh ElBordiny; Ashraf Ghandor; Abdelsalam Atteya; Reham Abdel Haleem Abo Elwafa; Aya Mohamed Mohamed ElSayed ElSokaily. "STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .". EKB Journal Management System, 4, 4, 2022, 33-34. doi: 10.21608/alexpo.2022.174858.1510
ElBordiny, M., Ghandor, A., Atteya, A., Abo Elwafa, R., ElSokaily, A. (2022). 'STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .', EKB Journal Management System, 4(4), pp. 33-34. doi: 10.21608/alexpo.2022.174858.1510
ElBordiny, M., Ghandor, A., Atteya, A., Abo Elwafa, R., ElSokaily, A. STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .. EKB Journal Management System, 2022; 4(4): 33-34. doi: 10.21608/alexpo.2022.174858.1510

STUDY OF EZH2 GENE TYROSINE 641 MUTAION IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA .

ALEXMED ePosters
Article 5, Volume 4, Issue 4, December 2022, Page 33-34  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.174858.1510
View on SCiNiTO View on SCiNiTO
Authors
Magdy Mamdouh ElBordiny1; Ashraf Ghandor2; Abdelsalam Atteya3; Reham Abdel Haleem Abo Elwafa4; Aya Mohamed Mohamed ElSayed ElSokaily email 5
1Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University
2Department of Internal Medicine, Faculty of Medicine, Alexandria University
3Department of clinical oncology and nuclear medicine, Faculty of medicine, Alexandria university.
4clinical pathology, faculty of medicine , Alexandria
5Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University
Abstract
Introduction: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified two subgroups of DLBCL; activated B-cell–like (ABC) and germinal-center Bcell–like (GCB) according to cell of origin. Diagnosis relies on a combination of morphologic findings (peripheral blood, bone marrow, or lymph node), immunohistochemistry, immunophenotyping, cytogenetics, fluorescence in situ hybridization (FISH) and molecular genetics. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) which implements transcriptional repression by trimethylation at lysine 27 of histone H3 (H3K27me3). It is important for normal immunoglobulin VDJ recombination in pre-B cells. EZH2 (Y641) mutations result in increased EZH2 stability and increased H3K27me3 activity, resulting in the repression of tumor suppressor genes. Its catalytic activity is closely correlated with tumor aggressiveness, drug resistance, and poor prognosis. Here, we studied 50 DLBCL biopsy samples using chain termination sequencing.

Aim: The aim of the study was to study the mutational status of enhancer of zeste homolog 2 (EZH2) gene tyrosine 641and its relation with different clinicopathological parameters in DLBCL patients.
Keywords
Diffuse large B cell lymphoma; Enhancer of Zeste homologue 2; Germinal center; Chain termination method
Supplementary Files
Statistics
Article View: 50